FDA Approves Subcutaneous Trastuzumab Formulation for HER2+ Breast Cancer

The US Food and Drug Administration has approved the subcutaneous administration of trastuzumab for patients with HER2-overexpressing breast cancer.

Source: CancerNetwork - March 5, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news